Urine Metabolites in the Diagnosis of Disease
NCT06710067
This study is recruiting at 4 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Colorectal Cancer
- Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
- Crohn Disease
- Celiac Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Luventix, Inc.
- Last updated on ClinicalTrials.gov
- December 13, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 4
- Unio Health Partners (Gastroenterology) · Encinitas, CA
- Digestive Health Associates · Santa Monica, CA
- Westside Gastro Care · Santa Monica, CA
- Bass Medical Group (Gastroenterology) · Walnut Creek, CA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.